NCT05028166Available不适用
Individual Patient Compassionate Use of Mirdametinib
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany0 个研究点开始时间: 2021年8月31日最近更新:
适应症
相关药物
试验速览
研究概览
简要总结
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 2 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted.
- •Patient does not qualify to participate in an ongoing clinical trial.
排除标准
- 未提供
研究者
相似试验
Available
不适用
Individual Patient Compassionate Use of NirogacestatDesmoid TumorNOTCH Gene Mutation Positive TumorsNCT05041036SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
撤回
不适用
Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere Inhalation SystemDiabetesNCT01459133South Orange County Endocrinology
Approved For Marketing
不适用
Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast CancerMetastatic Breast CancerNCT03763604Eli Lilly and Company
No Longer Available
不适用
A Compassionate Access Protocol For Those Patients Who Have Completed A4001029HIVNCT00801515ViiV Healthcare
Available
不适用
Fremanezumab Managed Access Program for Pediatric PatientsMigraineNCT03539393Teva Branded Pharmaceutical Products R&D LLC